50.97
0.73 (1.45%)
| Previous Close | 50.24 |
| Open | 51.30 |
| Volume | 529,217 |
| Avg. Volume (3M) | 527,918 |
| Market Cap | 3,222,512,128 |
| Price / Sales | 30.56 |
| Price / Book | 190.80 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -200.27% |
| Operating Margin (TTM) | -98.62% |
| Diluted EPS (TTM) | -4.34 |
| Quarterly Revenue Growth (YOY) | 72.60% |
| Total Debt/Equity (MRQ) | 69.13% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | -113.88 M |
| Levered Free Cash Flow (TTM) | -139.74 M |
| Return on Assets (TTM) | -45.78% |
| Return on Equity (TTM) | -155.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Rhythm Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.90 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.54% |
| % Held by Institutions | 107.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Primecap Management Co/Ca/ | 31 Mar 2025 | 5,787,322 |
| Frazier Life Sciences Management, L.P. | 31 Dec 2024 | 1,869,808 |
| Polar Capital Holdings Plc | 31 Dec 2024 | 1,500,000 |
| Westfield Capital Management Co Lp | 31 Mar 2025 | 1,341,092 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 92.00 (Canaccord Genuity, 80.50%) | Buy |
| Median | 78.00 (53.03%) | |
| Low | 68.00 (B of A Securities, 33.41%) | Buy |
| Average | 79.00 (54.99%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 56.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 07 May 2025 | 72.00 (41.26%) | Buy | 63.80 |
| 08 Apr 2025 | 66.00 (29.49%) | Buy | 57.73 | |
| B of A Securities | 10 Apr 2025 | 68.00 (33.41%) | Buy | 57.83 |
| Canaccord Genuity | 08 Apr 2025 | 92.00 (80.50%) | Buy | 57.73 |
| 27 Feb 2025 | 81.00 (58.92%) | Buy | 53.00 | |
| HC Wainwright & Co. | 08 Apr 2025 | 80.00 (56.96%) | Buy | 57.73 |
| 24 Mar 2025 | 70.00 (37.34%) | Buy | 53.72 | |
| Wells Fargo | 07 Apr 2025 | 91.00 (78.54%) | Buy | 54.96 |
| Morgan Stanley | 07 Mar 2025 | 72.00 (41.26%) | Buy | 50.79 |
| Stifel | 05 Mar 2025 | 78.00 (53.03%) | Buy | 52.97 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CRAMER PAMELA J. | - | 65.22 | -7,031 | -458,562 |
| MAZABRAUD YANN | - | 65.22 | -6,745 | -439,909 |
| Aggregate Net Quantity | -13,776 | |||
| Aggregate Net Value ($) | -898,471 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 65.22 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MAZABRAUD YANN | Officer | 29 Apr 2025 | Automatic sell (-) | 6,745 | 65.22 | 439,909 |
| CRAMER PAMELA J. | Officer | 29 Apr 2025 | Automatic sell (-) | 7,031 | 65.22 | 458,562 |
| CRAMER PAMELA J. | Officer | 29 Apr 2025 | Option execute | 7,031 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |